Costs of Sequelae Associated with Invasive Meningococcal Disease: Findings from a US Managed Care Population

 Funding for this study was provided by GlaxoSmithKline. GlaxoSmithKline also is conducting clinical research in meningococcal disease. The publication of the study results is not contingent upon the sponsors’ approval or censorship of the manuscript. Sudeep Karve, Keith Davis, and Derek Misurski were the primary developers of the study design. As principal investigator, Sudeep Karve had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Keith Davis and Sudeep Karve led all statistical analyses. Sudeep Karve also served as the primary writer in drafting the manuscript text and in interpreting the findings. Derek Misurski also assisted in obtaining the study data. Derek Misurski and Jacqueline Miller assisted in interpreting the study findings and drafting the manuscript text; they also served as the primary reviewers of the manuscript text. All authors were responsible for approving the manuscript and its contents.

 Sudeep Karve and Keith Davis are employees of RTI Health Solutions, an independent contract research organization that has received research funding from GlaxoSmithKline for this study. Derek Misurski and Jacqueline Miller are GlaxoSmithKline employees and shareholders.

PII: S1877-1319(11)00026-7

doi: 10.1016/j.ehrm.2011.08.001

© 2011 Elsevier Inc. All rights reserved.